Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Getting a biologic approved for a child with asthma or atopic dermatitis takes nearly a month on average — and that's only if it gets approved at all. A new study found that 39.3% of prior authorization requests for pediatric biologic prescriptions were denied, with insurance criteria failures and prerequisite therapy requirements as the top reasons. Researchers say the delays put kids at real risk for serious health outcomes.
Getting a biologic approved for a child with an atopic condition is a slow, uncertain process — and a new study puts hard numbers on just how burdensome it is. Presented at the ACAAI Annual Scientific Meeting, the retrospective review of 326 biologic prescriptions for pediatric patients (median age 12) found that prior authorization was required in 93.9% of cases. Of those, only 60.7% were approved — taking a mean of 32.7 days from prescription to green light.
The most commonly prescribed biologics were omalizumab (55.8%), dupilumab (26.1%), and mepolizumab (11.7%), used to treat conditions like asthma, atopic dermatitis, chronic urticaria, and IgE-mediated food allergy. Researchers flagged that over a quarter of all prescriptions required additional steps after initial submission, often due to insurers requesting more information — with no universal criteria across payers.
By the Numbers:
Why it matters: For children with high disease burden, delays in biologic access aren't just inconvenient — they can lead to serious or even fatal complications. Researchers hope the data drives meaningful conversations with payers to reduce barriers to guideline-supported pediatric care.